Perceptions of Canadian vascular surgeons toward pharmacological risk reduction in patients with peripheral arterial disease

Annals of Vascular Surgery

Volumn 20, Issue 5, 2006, Pages 555-563

  Al Omran, Mohammed ^a   Lindsay, Thomas F ^a   Major, Jennifer ^a   Jawas, Ali ^a   Leiter, Larry A ^b   Verma, Subodh ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG TARGETING; GLUCOSE BLOOD LEVEL; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PERCEPTION; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RISK FACTOR; RISK REDUCTION; SCREENING; SELF EVALUATION; SURGEON; VASCULAR SURGERY;

EID: 33845682045     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10016-006-9110-3     Document Type: Article

References (32)

1. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation 1997;96:44-49.
2. Fowkes FG, Housley E, Riemersma RA, et al. Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 1992;135:331-340.
3. Dormandy J, Mahir M, Ascady G, et al. Fate of the patient with chronic leg ischaemia. A review article. J Cardiovasc Surg (Torino) 1989;30:50-57.
4. Schroll M, Munck O. Estimation of peripheral arteriosclerotic disease by ankle blood pressure measurements in a population study of 60-year-old men and women. J Chronic Dis 1981;34:261-269.
5. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-515.
6. Holland WW, Raftery EB, McPherson P, Stone RW. A cardiovascular survey of American East Coast telephone workers. Am J Epidemiol 1967;85:61-71.
7. Hale WE, Marks RG, May FE, Moore MT, Stewart RB. Epidemiology of intermittent claudication: evaluation of risk factors. Age Ageing 1988;17:57-60.
8. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-743.
9. Al Omran M, Tu JV, Johnston KW, Mamdani MM, Kucey DS. Use of interventional procedures for peripheral arterial occlusive disease in Ontario between 1991 and 1998: a population-based study. J Vasc Surg 2003;38:289-295.
10. TASC Working Group. Managment of peripheral arterial disease (PAD): Trans-Atlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31(Suppl):S1- S288.
11. Hughson WG, Mann JI, Garrod A. Intermittent claudication: prevalence and risk factors. BMJ 1978;1:1379-1381.
12. Dormandy JA, Murray GD. The fate of the claudicant - a prospective study of 1969 claudicants. Eur J Vasc Surg 1991;5:131-133.
13. Malone JM, Moore WS, Goldstone J. Life expectancy following aortofemoral arterial grafting. Surgery 1977;81:551-555.
14. Hertzer N. Clinical experience with preoperative coronary angiography. J Vasc Surg 1985;2:510-512.
15. Turnipseed WD, Berkoff HA, Belzer FO. Postoperative stroke in cardiac and peripheral vascular disease. Ann Surg 1980;192:365-368.
16. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
17. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
19. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
20. Expert Panel on Detection EaToHBCiA. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
21. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003;289:2560-2571.
22. Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-1579.
23. Hirsch AT, Gloviczki P, Drooz A, Lovell M, Creager MA. Mandate for creation of a national peripheral arterial disease public awareness program: an opportunity to improve cardiovascular health. J Vasc Surg 2004;39:474-481.
24. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial disease. Results of a national physician survey. J Gen Intern Med 2002;17:895-904.
25. Cassar K, Belch JJ, Brittenden J. Are national cardiac guidelines being applied by vascular surgeons? Eur J Vasc Endovasc Surg 2003;26:623-628.
26. Cassar K, Coull R, Bachoo P, Macaulay E, Brittenden J. Management of secondary risk factors in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2003;26:262-266.
27. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324.
28. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
29. American Diabetes Association. Position statement. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26:S33-S50.
30. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
31. Abramson BL, Huckell V, Anand S, et al. Canadian Cardiovascular Society Consensus Conference. Peripheral arterial disease-executive summary. Can J Cardiol 2005;21:997-1006.
32. Davis DA, Taylor-Vaisey A. Translating guidelines into practice: a systematic review of theoretic concepts, practical experience and research evidence in the adoption of clinical practice guidelines. CMAJ 1997;157:408-416.